The brain Renin-Angiotensin System (RAS) plays a pivotal role in controlling cardiometabolic homeostasis, fluid balance, and other functions including inflammation. Previous studies have shown that more than a thousand microRNA (miRNA) families regulate RAS genes expression, and their dysregulation has been associated with HTN, cardiac ischemia, and aging. Recently, we observed that hypercaloric diet (HCD) programming resulted in differentially expressed miRNA in the hypothalamus of only the male progeny, including miR-410-3p which is thought to target angiotensin-II type 1 receptors (AT1R). Here, we aimed to investigate whether miR-410-3p regulate AT1R expression in a mouse model of cardiometabolic disease (CMD) exhibiting hypertension, diabetes and obesity. C57BI/6J mice (3-week-old, both sexes, n=10) were fed a HCD (D12492. 60 kcal% Fat, Research Diets, USA) while weight and fasting blood glucose levels were measured weekly to ensure the acquisition of metabolic syndrome. At 12 weeks of age, the mice were infused subcutaneously (osmotic pump model 1004, Alzet) with Ang-II (600 ng/kg/min/4 weeks). Gene expression of miR-410-3p (QRT-PCR) was reduced in the hypothalamus of CMD male mice (0.5 ±0.1 vs.1.0 ±0.1, p<0.05) but increased in females (1.6 ±0.4 vs.0.7 ±0.2, p<0.001), while both sexes showed a reduction in the heart (Males: 0.2 ±0.0 vs.1.7 ±0.3; Females: 0.23 ±0.0 vs. 3.2 ±0.3, p<0.01). AT1R protein expression (Capillary Western) was increased in the hypothalamus of CMD male (1.5 ±0.1 vs.1.0 ±0.2, p<0.05) mice but not in females (1.0 ±0.1 vs.1.2 ±0.1, P>0.05) while both sexes exhibited elevated levels in the heart (Males: 2.0 ±0.1 vs. 1.0 ±0.1; Females: 2.3 ±0.1 vs. 1.3 ±0.2, p<0.05). Binding specificity (luciferase assay) was further assessed between miR-410-3p and the 3’UTR of AT1R. Binding was decreased in presence of miR410-3p mimic (0.9 ±0.0 vs. 2.1 ±0.0; p<0.001) and enhanced by a miR410-3p inhibitor (2.5 ±0.1 vs. 2.1 ±0.0; p<0.01), confirming that AT1R is a direct target of miR410-3p. Together, our data suggest that in CMD downregulation of miR410-3p is associated with the upregulation of AT1R both in the hypothalamus and heart, notably in males. This positions miR410-3p as a possible new therapeutic strategy to control RAS overactivity in CMD. This work was supported in part by a research grant from the National Institutes of Health (HL163588). This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.